Bone Biologics Corp BBLG.OQ reported a quarterly adjusted loss of 67 cents per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $-3.84. The lone analyst forecast for the quarter was for a loss of $1.39 per share.
Reported revenue was zero; analysts expected zero.
Bone Biologics Corp's reported EPS for the quarter was a loss of 67 cents.
The company reported a quarterly loss of $783 thousand.
Bone Biologics Corp shares had risen by 30.3% this quarter and lost 64.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 81.5% in the last three months.
In the last 30 days, there have been earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
Wall Street's median 12-month price target for Bone Biologics Corp is $19.50
This summary was machine generated from LSEG data August 9 at 10:14 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING |
ESTIMATE |
ACTUAL |
BEAT, MET, MISSED |
Jun. 30 2024 |
-1.39 |
-0.67 |
Beat |
Mar. 31 2024 |
-7.60 |
-1.31 |
Beat |
Dec. 31 2023 |
-5.60 |
-2.47 |
Beat |
Sep. 30 2023 |
-24.32 |
-4.88 |
Beat |